Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tergenpumatucel-L - NewLink Genetics Corporation

Drug Profile

Tergenpumatucel-L - NewLink Genetics Corporation

Alternative Names: HyperAcute Lung; HyperAcute Lung immunotherapy; Lung cancer vaccine - NewLink Genetics; Turgenpumatucel-L

Latest Information Update: 08 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Non-small cell lung cancer

Most Recent Events

  • 26 Feb 2019 NewLink Genetics Corporation terminates a phase II/III trial in Non-small cell lung cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (NCT01774578)
  • 31 Aug 2018 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intradermal)
  • 03 Nov 2015 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intradermal) (NCT02460367)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top